




CORRECTION

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^{V600}-mutant advanced melanoma patients: a propensity-matched survival analysis

Jesper van Breeschoten, Michel W. J. M. Wouters, Doranne L. Hilarius, John B. Haanen, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Jan-Willem B. de Groot, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Roos S. van Rijn, Karijn P. M. Suijkerbuijk, Willeke A. M. Blokx, Bert-Jan J. ten Tije, Astrid A. M. van der Veldt , Art Vreugdenhil, Marye J. Boers-Sonderen and Alfonsus J. M. van den Eertwegh

British Journal of Cancer (2021) 124:1746; <https://doi.org/10.1038/s41416-021-01312-1>

Correction to: *British Journal of Cancer* <https://doi.org/10.1038/s41416-020-01229-1>, published online 26 January 2021

Since the publication of this paper, the authors have noticed an error in the Abstract where the value for the 2-year overall survival

for patients receiving anti-PD-1 antibodies was incorrectly given as 85.4% (95% CI: 58.1–73.6) rather than the correct value of 65.4% (95% CI: 58.1–73.6). This has been corrected. The authors would like to apologise for this error, which does not alter the conclusions of the paper.